Premium
Inhibition of gastric acid secretion in the conscious dog by the mast‐cell stabilizing agent, FPL 52694
Author(s) -
Canfield S.P.,
Curwain B.P.
Publication year - 1983
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/j.1476-5381.1983.tb11045.x
Subject(s) - pentagastrin , histamine , stimulation , gastric acid , endocrinology , medicine , cimetidine , secretion , mast cell , stomach , chemistry , immunology
1 The effects of the mast‐cell stabilizing agent, FPL 52694, on gastric acid secretion in conscious dogs with gastric fistulae have been studied. 2 FPL 52694 (5 or 10 mg kg −1 h −1 ) given intravenously during a plateau response to pentagastrin stimulation (2 μg'kg −1 h −1 ) caused a maximum inhibition of acid output of about 50% but had no significant effect on volume output so that the [H + ] in the juice was markedly reduced. The ratio of mucosal blood flow/acid output (Ra) was increased in the presence of FPL 52694. There was no maintained reduction of [H + ] when inhibition was due to cimetidine (4 μmol kg −1 , i.V.). 3 Instillation of FPL 52694 (4.35 mg ml −1 ) directly into the stomach via the fistula for 30 min also resulted in an inhibition of acid output and reduction of [H + ] during both pentagastrin‐(2 μg kg −1 h −1 ) and histamine‐stimulated (30 μg kg −1 h −1 ) secretion. Inhibition of pentagastrin‐stimulated acid output by intragastric administration of FPL 52694 was much greater than the maximum effect seen following intravenous infusion. 4 The results are discussed in relation to the possible mode of action of FPL 52694. It is concluded that FPL 52694 is active orally and has a novel action on acid secretion which may include stimulation of gastric bicarbonate secretion.